LAUSR

ysis of Tfh markers, many kinds of Tfh markers in PTCL with Tfhphenotype are less observed than AITL and more than PTCL, NOS. Among clinicopathological features of PTCL with Tfh-phenotype, cases with PS≥2 (P = 0.001), elevated CRP (P = 0.020), and bcl6-negative (P = 0.008) showed significantly poorer OS curve, respectively. Conclusions: PTCL with Tfh-phenotype should be considered clinicopathologically as disease entity distributed between AITL and PTCL, NOS. Prognostic markers might be useful for stratification of clinical strategy. More investigation including genomic abnormalities and mRNA expression would be desired to confirm the results of this study.